Drugs that contain Cetirizine Hydrochloride
1. Drug name - QUZYTTIR
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8513259 | JDP | Non-sedating antihistamine injection formulations and methods of use thereof |
Feb, 2030
(7 years from now) | |
| US9180090 | JDP | Non-sedating antihistamine injection formulations and methods of use thereof |
Feb, 2030
(7 years from now) | |
| US9119771 | JDP | Non-sedating antihistamine injection formulations and methods of use thereof |
Feb, 2030
(7 years from now) | |
| US8314083 | JDP | Non-sedating antihistamine injection formulations and methods of use thereof |
Feb, 2030
(7 years from now) | |
| US8263581 | JDP | Non-sedating antihistamine injection formulations and methods of use thereof |
Feb, 2030
(7 years from now) | |
Treatment: Method of increasing peak plasma or onset of plasma concentration by intravenous injection in individuals in need of treatment for acute urticaria; Treatment of acute urticaria; Method of treatment in patients with concomitant angioedema
Dosage: SOLUTION;INTRAVENOUS
More Information on Dosage
| Strength | Dosage | Availability |
|---|---|---|
| 10MG/ML (10MG/ML) | SOLUTION;INTRAVENOUS | Prescription |
2. Drug name - ZERVIATE
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9993471 | EYEVANCE | Ophthalmic formulations of cetirizine and methods of use |
Mar, 2030
(7 years from now) | |
| US8829005 | EYEVANCE | Ophthalmic formulations of cetirizine and methods of use |
Mar, 2030
(7 years from now) | |
| US9750684 | EYEVANCE | Ophthalmic formulations of cetirizine and methods of use |
Mar, 2030
(7 years from now) | |
|
US8829005
(Pediatric) | EYEVANCE | Ophthalmic formulations of cetirizine and methods of use |
Sep, 2030
(7 years from now) | |
| US9254286 | EYEVANCE | Ophthalmic formulations of cetirizine and methods of use |
Jul, 2032
(9 years from now) | |
|
US9254286
(Pediatric) | EYEVANCE | Ophthalmic formulations of cetirizine and methods of use |
Jan, 2033
(10 years from now) | |
Treatment: Treatment of ocular itching associated with allergic conjunctivitis
Dosage: SOLUTION/DROPS;OPHTHALMIC
More Information on Dosage
| Strength | Dosage | Availability |
|---|---|---|
| EQ 0.24% BASE | SOLUTION/DROPS;OPHTHALMIC | Prescription |
availability in other generic markets.
Click on the highlighted region to filter.